279 related articles for article (PubMed ID: 35578055)
1. Repurposing the natural compounds as potential therapeutic agents for COVID-19 based on the molecular docking study of the main protease and the receptor-binding domain of spike protein.
Eskandari V
J Mol Model; 2022 May; 28(6):153. PubMed ID: 35578055
[TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
3. Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry.
Zhang D; Hamdoun S; Chen R; Yang L; Ip CK; Qu Y; Li R; Jiang H; Yang Z; Chung SK; Liu L; Wong VKW
Pharmacol Res; 2021 Oct; 172():105820. PubMed ID: 34403732
[TBL] [Abstract][Full Text] [Related]
4. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
5. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
6. Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2.
Prajapat M; Shekhar N; Sarma P; Avti P; Singh S; Kaur H; Bhattacharyya A; Kumar S; Sharma S; Prakash A; Medhi B
J Mol Graph Model; 2020 Dec; 101():107716. PubMed ID: 32866780
[TBL] [Abstract][Full Text] [Related]
7. Molecular Interactions of Tannic Acid with Proteins Associated with SARS-CoV-2 Infectivity.
Haddad M; Gaudreault R; Sasseville G; Nguyen PT; Wiebe H; Van De Ven T; Bourgault S; Mousseau N; Ramassamy C
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269785
[TBL] [Abstract][Full Text] [Related]
8. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
Shahbazi B; Mafakher L; Teimoori-Toolabi L
J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
[TBL] [Abstract][Full Text] [Related]
9. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
10. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
12. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
13. Network pharmacology, molecular docking, and dynamics analyses to predict the antiviral activity of ginger constituents against coronavirus infection.
Samy A; Hassan A; Hegazi NM; Farid M; Elshafei M
Sci Rep; 2024 May; 14(1):12059. PubMed ID: 38802394
[TBL] [Abstract][Full Text] [Related]
14. ADMET profile and virtual screening of plant and microbial natural metabolites as SARS-CoV-2 S1 glycoprotein receptor binding domain and main protease inhibitors.
Padhi S; Masi M; Chourasia R; Rajashekar Y; Rai AK; Evidente A
Eur J Pharmacol; 2021 Jan; 890():173648. PubMed ID: 33069672
[TBL] [Abstract][Full Text] [Related]
15. A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study.
Novak J; Potemkin VA
Mol Divers; 2022 Oct; 26(5):2631-2645. PubMed ID: 35001230
[TBL] [Abstract][Full Text] [Related]
16. Mulberry Component Kuwanon C Exerts Potent Therapeutic Efficacy In Vitro against COVID-19 by Blocking the SARS-CoV-2 Spike S1 RBD:ACE2 Receptor Interaction.
Kim YS; Kwon EB; Kim B; Chung HS; Choi G; Kim YH; Choi JG
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293371
[TBL] [Abstract][Full Text] [Related]
17. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.
Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS
Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175
[TBL] [Abstract][Full Text] [Related]
18.
Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
[TBL] [Abstract][Full Text] [Related]
19. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
Vardhan S; Sahoo SK
Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
[TBL] [Abstract][Full Text] [Related]
20. Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2: A Combined in silico and in vitro Study.
Durdagi S; Orhan MD; Aksoydan B; Calis S; Dogan B; Sahin K; Shahraki A; Iyison NB; Avsar T
Mol Inform; 2022 Feb; 41(2):e2100062. PubMed ID: 34529322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
